Bioprosthetic tricuspid valve regurgitation associated with pacemaker or defibrillator lead implantation

Mackram Eleid, Lori A. Blauwet, Yong-Mei Cha, Heidi M. Connolly, Peter A. Brady, Joseph A. Dearani, Raul Emilio Espinosa

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objectives: The goal of this study was to determine the impact of transvenous pacemaker and defibrillator leads on the incidence of bioprosthetic tricuspid valve (BTV) regurgitation compared with BTV patients without a transvalvular lead. Background: Although concern has been raised regarding the potential deleterious effect of permanent transvenous device leads on BTV function, little is known about the incidence of prosthetic tricuspid regurgitation (TR) after lead placement. Methods: A retrospective review of 58 patients who underwent BTV implantation and subsequently required endocardial pacemaker (n = 52) or defibrillator (n = 6) lead implantation across the BTV was conducted. Patient and prosthesis characteristics, lead type, and clinical events were collected. The incidence and severity of prosthetic TR, determined by Doppler echocardiography, was compared with 265 consecutive patients who underwent BTV implantation without undergoing subsequent transvalvular device lead implantation. Results: Over a mean follow-up of 25 months, in 5 patients (9%) with a transvalvular lead significant (moderate or greater) prosthetic TR developed compared with 12 patients (5%) in the control group (p = 0.20). Kaplan-Meier analysis revealed no significant difference in the incidence of TR in BTV patients with and without transvalvular leads (p = 0.45). Significant prosthetic TR in patients with and without a transvalvular lead more commonly occurred 2 years or later after lead or BTV implantation (4 of 5, 80% and 10 of 12, 83%, respectively). Conclusions: Transvalvular device lead implantation in BTV patients was not associated with an increased incidence of significant prosthetic TR (p = 0.45). Based on these data, transvalvular lead implantation appears to be an acceptable approach for patients with a BTV who require permanent pacemaker or defibrillator placement.

Original languageEnglish (US)
Pages (from-to)813-818
Number of pages6
JournalJournal of the American College of Cardiology
Volume59
Issue number9
DOIs
StatePublished - Feb 28 2012

Fingerprint

Tricuspid Valve Insufficiency
Defibrillators
Tricuspid Valve
Incidence
Equipment and Supplies
Lead
Doppler Echocardiography
Kaplan-Meier Estimate
Prostheses and Implants

Keywords

  • bioprosthetic tricuspid valve
  • pacemaker
  • prosthetic tricuspid regurgitation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Bioprosthetic tricuspid valve regurgitation associated with pacemaker or defibrillator lead implantation. / Eleid, Mackram; Blauwet, Lori A.; Cha, Yong-Mei; Connolly, Heidi M.; Brady, Peter A.; Dearani, Joseph A.; Espinosa, Raul Emilio.

In: Journal of the American College of Cardiology, Vol. 59, No. 9, 28.02.2012, p. 813-818.

Research output: Contribution to journalArticle

@article{37dcfd1ad08b48aba49bde70ad3ddd9b,
title = "Bioprosthetic tricuspid valve regurgitation associated with pacemaker or defibrillator lead implantation",
abstract = "Objectives: The goal of this study was to determine the impact of transvenous pacemaker and defibrillator leads on the incidence of bioprosthetic tricuspid valve (BTV) regurgitation compared with BTV patients without a transvalvular lead. Background: Although concern has been raised regarding the potential deleterious effect of permanent transvenous device leads on BTV function, little is known about the incidence of prosthetic tricuspid regurgitation (TR) after lead placement. Methods: A retrospective review of 58 patients who underwent BTV implantation and subsequently required endocardial pacemaker (n = 52) or defibrillator (n = 6) lead implantation across the BTV was conducted. Patient and prosthesis characteristics, lead type, and clinical events were collected. The incidence and severity of prosthetic TR, determined by Doppler echocardiography, was compared with 265 consecutive patients who underwent BTV implantation without undergoing subsequent transvalvular device lead implantation. Results: Over a mean follow-up of 25 months, in 5 patients (9{\%}) with a transvalvular lead significant (moderate or greater) prosthetic TR developed compared with 12 patients (5{\%}) in the control group (p = 0.20). Kaplan-Meier analysis revealed no significant difference in the incidence of TR in BTV patients with and without transvalvular leads (p = 0.45). Significant prosthetic TR in patients with and without a transvalvular lead more commonly occurred 2 years or later after lead or BTV implantation (4 of 5, 80{\%} and 10 of 12, 83{\%}, respectively). Conclusions: Transvalvular device lead implantation in BTV patients was not associated with an increased incidence of significant prosthetic TR (p = 0.45). Based on these data, transvalvular lead implantation appears to be an acceptable approach for patients with a BTV who require permanent pacemaker or defibrillator placement.",
keywords = "bioprosthetic tricuspid valve, pacemaker, prosthetic tricuspid regurgitation",
author = "Mackram Eleid and Blauwet, {Lori A.} and Yong-Mei Cha and Connolly, {Heidi M.} and Brady, {Peter A.} and Dearani, {Joseph A.} and Espinosa, {Raul Emilio}",
year = "2012",
month = "2",
day = "28",
doi = "10.1016/j.jacc.2011.10.893",
language = "English (US)",
volume = "59",
pages = "813--818",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "9",

}

TY - JOUR

T1 - Bioprosthetic tricuspid valve regurgitation associated with pacemaker or defibrillator lead implantation

AU - Eleid, Mackram

AU - Blauwet, Lori A.

AU - Cha, Yong-Mei

AU - Connolly, Heidi M.

AU - Brady, Peter A.

AU - Dearani, Joseph A.

AU - Espinosa, Raul Emilio

PY - 2012/2/28

Y1 - 2012/2/28

N2 - Objectives: The goal of this study was to determine the impact of transvenous pacemaker and defibrillator leads on the incidence of bioprosthetic tricuspid valve (BTV) regurgitation compared with BTV patients without a transvalvular lead. Background: Although concern has been raised regarding the potential deleterious effect of permanent transvenous device leads on BTV function, little is known about the incidence of prosthetic tricuspid regurgitation (TR) after lead placement. Methods: A retrospective review of 58 patients who underwent BTV implantation and subsequently required endocardial pacemaker (n = 52) or defibrillator (n = 6) lead implantation across the BTV was conducted. Patient and prosthesis characteristics, lead type, and clinical events were collected. The incidence and severity of prosthetic TR, determined by Doppler echocardiography, was compared with 265 consecutive patients who underwent BTV implantation without undergoing subsequent transvalvular device lead implantation. Results: Over a mean follow-up of 25 months, in 5 patients (9%) with a transvalvular lead significant (moderate or greater) prosthetic TR developed compared with 12 patients (5%) in the control group (p = 0.20). Kaplan-Meier analysis revealed no significant difference in the incidence of TR in BTV patients with and without transvalvular leads (p = 0.45). Significant prosthetic TR in patients with and without a transvalvular lead more commonly occurred 2 years or later after lead or BTV implantation (4 of 5, 80% and 10 of 12, 83%, respectively). Conclusions: Transvalvular device lead implantation in BTV patients was not associated with an increased incidence of significant prosthetic TR (p = 0.45). Based on these data, transvalvular lead implantation appears to be an acceptable approach for patients with a BTV who require permanent pacemaker or defibrillator placement.

AB - Objectives: The goal of this study was to determine the impact of transvenous pacemaker and defibrillator leads on the incidence of bioprosthetic tricuspid valve (BTV) regurgitation compared with BTV patients without a transvalvular lead. Background: Although concern has been raised regarding the potential deleterious effect of permanent transvenous device leads on BTV function, little is known about the incidence of prosthetic tricuspid regurgitation (TR) after lead placement. Methods: A retrospective review of 58 patients who underwent BTV implantation and subsequently required endocardial pacemaker (n = 52) or defibrillator (n = 6) lead implantation across the BTV was conducted. Patient and prosthesis characteristics, lead type, and clinical events were collected. The incidence and severity of prosthetic TR, determined by Doppler echocardiography, was compared with 265 consecutive patients who underwent BTV implantation without undergoing subsequent transvalvular device lead implantation. Results: Over a mean follow-up of 25 months, in 5 patients (9%) with a transvalvular lead significant (moderate or greater) prosthetic TR developed compared with 12 patients (5%) in the control group (p = 0.20). Kaplan-Meier analysis revealed no significant difference in the incidence of TR in BTV patients with and without transvalvular leads (p = 0.45). Significant prosthetic TR in patients with and without a transvalvular lead more commonly occurred 2 years or later after lead or BTV implantation (4 of 5, 80% and 10 of 12, 83%, respectively). Conclusions: Transvalvular device lead implantation in BTV patients was not associated with an increased incidence of significant prosthetic TR (p = 0.45). Based on these data, transvalvular lead implantation appears to be an acceptable approach for patients with a BTV who require permanent pacemaker or defibrillator placement.

KW - bioprosthetic tricuspid valve

KW - pacemaker

KW - prosthetic tricuspid regurgitation

UR - http://www.scopus.com/inward/record.url?scp=84857329638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857329638&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2011.10.893

DO - 10.1016/j.jacc.2011.10.893

M3 - Article

C2 - 22361401

AN - SCOPUS:84857329638

VL - 59

SP - 813

EP - 818

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 9

ER -